文献速递其他结缔组织病

应用适配体蛋白质组学分析识别新型系统性硬化症生物标志物

Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本文综述了应用适配体蛋白质组学分析识别系统性硬化症(SSc)及由近期起病的雷诺现象(RP)进展为SSc的新型无创生物标志物的背景与依据。文章指出SSc及SSc相关RP缺乏敏感特异的生物标志物,适配体蛋白质组学平台的大规模应用将对SSc患者的精准与个体化医疗具有重要价值,并与其它风湿炎症及自身免疫疾病的蛋白质组学生物标志物研究进行了比较。

要点

  • SSc诊断、疾病活动度、内脏受累范围、治疗反应和预后均缺乏经临床验证的无创生物标志物。
  • 缺乏敏感特异的生物标志物是SSc及SSc相关RP优化临床管理的限制因素。
  • 适配体蛋白质组学可特异性识别更多蛋白质,为生物标志物发现开辟新前景。

核心结论

  • 适配体蛋白质组学平台的大规模应用将对SSc患者的精准与个体化医疗具有重要价值。

研究设计与样本

  • 本文为综述,围绕应用适配体蛋白质组学分析识别SSc及由近期起病RP进展为SSc的新型无创生物标志物的背景与依据展开,并与其它风湿炎症及自身免疫疾病的蛋白质组学生物标志物研究进行比较。

主要发现

  • SSc诊断、疾病活动度评估、内脏受累范围、治疗反应和预后均存在未满足的经临床验证无创生物标志物需求。
  • 缺乏敏感特异的生物标志物是SSc及SSc相关RP优化临床管理的限制因素。
  • 适配体技术发展及可特异性识别蛋白质数量的扩展为生物标志物发现开辟了新前景。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an important unmet need for clinically validated non-invasive biomarkers for SSc diagnosis, assessment of disease activity, extent of internal organ involvement, therapeutic response and prognosis. There is also an unmet need for biomarkers to accurately differentiate primary RP from recent onset RP evolving into SSc. The lack of sensitive and specific biomarkers for SSc and SSc-associated RP is a limitation for the optimal clinical management of these patients. The development of highly sensitive and specific proteomic analysis employing aptamers and the expansion in the number of proteins that can be specifically identified by aptamer proteomics have opened new horizons for biomarker discovery. Here, we review the background and rationale for aptamer proteomic analysis for the identification of novel non-invasive biomarkers for SSc and recent onset RP evolving into SSc. Large scale application of aptamer proteomic platforms for this purpose will be of substantial value for the precision and personalized medical care of SSc patients. These studies will be placed in context by comparison with proteomic biomarker studies performed for other rheumatological inflammatory and autoimmune diseases.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wermuth PJ, Piera-Velazquez S, Jimenez SA, et al. Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis. Rheumatology (Oxford). 2018. PMID: 29140474. doi:10.1093/rheumatology/kex404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。